CAMIDANLUMAB TESIRINE EFFICACY AND SAFETY IN AN OPEN‐LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS (PTS) WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)
In: Hematological oncology, Jg. 39 (2021)
Online
serialPeriodical
Zugriff:
Titel: |
CAMIDANLUMAB TESIRINE EFFICACY AND SAFETY IN AN OPEN‐LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS (PTS) WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)
|
---|---|
Autor/in / Beteiligte Person: | Zinzani, P. L. ; Carlo‐Stella, C. ; Hamadani, M. ; Herrera, A. F. ; Ansell, S. M. ; Radford, J. ; Maddocks, K. ; Kline, J. ; Savage, K. J. ; Bartlett, N. L. ; Caimi, P. F. ; Negievich, Y. ; Cruz, H. G. ; Wang, L. ; Wuerthner, J. ; Collins, G. P. |
Link: | |
Zeitschrift: | Hematological oncology, Jg. 39 (2021) |
Veröffentlichung: | 2021 |
Medientyp: | serialPeriodical |
ISSN: | 0278-0232 (print) |
Sonstiges: |
|